TATA Health International Holdings announced a clarification to its 27 August 2026 profit warning, lowering the projected loss attributable to shareholders for the six months ended 30 June 2026 from approximately HK$12.40 million to no more than HK$1.50 million.

The Board attributed the change to the rectification of minor clerical inaccuracies discovered during a post-issuance review of the Group’s latest unaudited consolidated financial statements. Apart from the revised loss estimate, all other information in the original profit warning remains unchanged.

Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares, the statement added.

TATA Health’s Board currently comprises one executive director (Zhang Ming Qi), one non-executive director (Chen Qi) and four independent non-executive directors (Huang Lin, Li Liang, Du Jianfeng and Tan Kaiguo).